The earlier, the smaller, the better for natalizumab-associated PML: In MRI vigilance veritas?

Neurology

Volumn 79, Issue 10, 2012, Pages 1067-1069

  Phan Ba, Rémy ^a,b   Belachew, Shibeshih ^a,b   Outteryck, Olivier ^c   Moonen, Gustave ^b   Sindic, Christian ^d   Vokaer, Mathieu ^e,f   Vermersch, Patrick ^c  

^a MYelin Disorders REseArch TeaM (MYDREAM)   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c UNIV LILLE   (France)

^d CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^e MYelin Disorders REseArch teaM (MYDREAM)   (Belgium)

^f ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

NATALIZUMAB;

ARTICLE; CASE REPORT; DRUG UTILIZATION; FRANCE; HUMAN; INFORMED CONSENT; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY;

EID: 84866075510     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31826846b4     Document Type: Article

References (7)

1. Sorensen PS, Bertolotto A, Edan G, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler 2012;18:143-152.
2. Kappos L, Bates D, Edan G, et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol 2011;10:745-758.
3. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 2010;68:295-303.
4. Phan-Ba R, Lommers E, Tshibanda L, et al. MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy. J Neurol Neurosurg Psychiatry 2012;83:224-226.
5. Vermersch P, Kappos L, Gold R, et al. Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology 2011;76:1697-1704.
6. Vennegoor A, Wattjes MP, van Munster ET, et al. Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS. Neurology 2011;76:574-576.
7. Linda H, von Heijne A, Major EO, et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med 2009;361:1081-1087.